Nektar Therapeutics (NASDAQ: NKTR) reported Q2 EPS of $5.33, $0.11 better than the analyst estimate of $5.22. Revenue for the quarter came in at $1.09 billion versus the consensus estimate of $1.03 billion.

For earnings history and earnings-related data on Nektar Therapeutics (NKTR) click here.